METHOD FOR ISSUING T-CELLS WITH ANTIGEN SPECIFICITY FOR A CANCER-SPECIFIC P53 MUTATION
Patent Information
- Application Number
- DE602018080973
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-09-29
- Filing Date
- 2018-09-17
- Publication Date
- 2025-04-09
- Estimated Expiration
- 2038-09-17
AI Technical Summary
Current methods for adoptive cell therapy (ACT) face challenges in identifying and isolating T cells that specifically recognize cancer antigens, particularly those with mutated human p53 amino acid sequences.
A method is developed to isolate T cells with antigenic specificity for mutated human p53 amino acid sequences by inducing autologous antigen-presenting cells (APCs) to present these sequences. This is achieved through pulsing APCs with peptides or introducing nucleotide sequences encoding the mutated p53 sequences, followed by co-culturing with autologous T cells and selecting those with antigenic specificity.
The method effectively isolates T cells that specifically recognize mutated p53 sequences, potentially enhancing the efficacy of ACT by targeting cancer cells while minimizing damage to normal cells.